Physician profile
Heather Lee Lockner
NPI 1295774503
$2,870.13
in general payments reported to CMS, 2019-2025
36 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $589 · 2021: $651 · 2022: $381 · 2023: $235 · 2024: $198 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $317.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $308.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $208.66 | 2019-2021 | |
| Pfizer INC. | $200.20 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.12 | 2019-2022 | |
| Amarin Pharma, INC. | $166.97 | 2019-2021 | |
| Lilly USA, LLC | $147.78 | 2019-2025 | Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $129.13 | 2019-2022 | |
| Abbott Laboratories | $127.62 | 2021-2024 | Freestyle Libre 2, Octrode |
| Astellas Pharma US INC | $98.59 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $87.00 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $72.57 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.29 | 2021-2022 | |
| Bausch Health US, LLC | $59.64 | 2020-2024 | Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $55.85 | 2020-2023 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $55.40 | 2023-2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $46.83 | 2024 | Leqembi |
| Alexion Pharmaceuticals, INC. | $44.46 | 2020 | |
| Adlon Therapeutics L.P. | $44.37 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.78 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $43.01 | 2020-2021 | |
| Eisai INC. | $40.71 | 2020 | |
| Novartis Pharmaceuticals Corporation | $37.90 | 2019 | |
| Glaxosmithkline, LLC. | $34.50 | 2019-2022 | |
| Allergan, INC. | $32.27 | 2020 | |
| Exact Sciences Corporation | $30.71 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.62 | 2022 | |
| Gilead Sciences, INC. | $23.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.62 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.40 | 2023 | Gvoke Hypopen |
| Inari Medical, INC. | $19.24 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Corium, LLC | $19.13 | 2022 | |
| Celgene Corporation | $18.31 | 2019 | |
| Shire North American Group INC | $15.70 | 2019 | |
| Sanofi Pasteur INC. | $15.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lockner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.